Has PCOS been renamed?

Yes. In May 2026, a multistep global consensus process published in The Lancet renamed polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS). Helena Teede of Monash University led the consensus paper. The new name better reflects the metabolic and endocrine nature of the condition and removes the misleading 'cyst' framing.

What does PMOS stand for?

PMOS stands for Polyendocrine Metabolic Ovarian Syndrome. The acronym replaces PCOS (Polycystic Ovary Syndrome). The new name keeps the ovarian connection but emphasizes the broader endocrine and metabolic involvement, including insulin resistance, androgen excess, and metabolic dysregulation.

Why was PCOS renamed?

The previous name was considered inaccurate. It implies pathological cysts on the ovaries when the visible structures are actually arrested follicles, not true cysts. The old name also obscured the diverse endocrine and metabolic features of the condition, contributed to delayed diagnosis, fragmented care across specialties, and created stigma.

Helena Teede is a professor of women's health at Monash University in Australia. She has led the international evidence-based guidelines for PCOS since 2018 and served as lead author of the 2026 Lancet consensus paper that formalized the rename to PMOS. She is the dominant clinical voice in PCOS/PMOS research globally.

When does the new name take effect?

The Lancet paper was published in May 2026. Medical societies, electronic health record systems, ICD coding bodies, and patient-facing literature will adopt the new term over months to years. Both names will be used in parallel during the transition. Current PCOS diagnoses do not need to be re-issued; the underlying condition and criteria are unchanged.

PCOS renamed to PMOS

If you have followed PCOS news in May 2026, you have probably seen "PMOS" appearing in headlines, medical newsletters, and patient forums. This post explains what changed, who made the change, why it happened now, and what it means if you have been diagnosed with PCOS or suspect you might be.

What changed

In May 2026, The Lancet published a paper led by Professor Helena Teede of Monash University. The paper formalized a name change agreed through a multistep global consensus process involving clinicians, researchers, and patient representatives.

The condition previously called polycystic ovary syndrome (PCOS) is now called polyendocrine metabolic ovarian syndrome (PMOS).

The shorthand is straightforward:

Old name: PCOS (Polycystic Ovary Syndrome)
New name: PMOS (Polyendocrine Metabolic Ovarian Syndrome)

The diagnostic criteria are the same. The Rotterdam criteria, the international evidence-based guidelines, and the underlying biology have not been changed by this announcement. The clinical condition is identical. What changed is the label.

Why the old name was misleading

The Lancet paper laid out the reasoning in plain clinical terms. The previous name was considered inaccurate on three counts.

The "cysts" are not cysts. The structures visible on ovarian ultrasound in PCOS are arrested follicles, not true cysts. They are immature follicles that did not complete the ovulation process. Calling them cysts implied a pathological growth that needed to be addressed surgically or removed, which is not how the condition works.

The name centered the ovaries. PCOS is not just an ovarian condition. It involves the hypothalamus, the pituitary, the adrenal glands, insulin metabolism, and adipose tissue. Centering the ovaries in the name caused care to fragment, with gynecologists, endocrinologists, dermatologists, and primary care providers each treating their corner of the condition without a unifying frame.

The metabolic component was hidden. Insulin resistance, weight regulation difficulty, increased cardiovascular risk, and type 2 diabetes risk are central features of the condition. The old name did not signal any of this. Patients and primary care providers often did not realize that PCOS care required metabolic surveillance.

The Lancet authors explicitly cite delayed diagnosis, fragmented care, and stigma as harms caused by the old name.

What "polyendocrine metabolic ovarian syndrome" captures

The new name unpacks deliberately:

Polyendocrine: multiple endocrine systems are involved, including the hypothalamic-pituitary-ovarian axis, insulin signaling, and the adrenals.
Metabolic: insulin resistance, metabolic dysregulation, and cardiovascular risk are intrinsic features, not side effects.
Ovarian: the ovarian involvement remains, but as one feature among several rather than the defining one.
Syndrome: still a syndrome, meaning a constellation of features rather than a single defined disease.

The acronym keeps the same letter count and stays pronounceable. The renaming committee considered keeping "PCOS" with reinterpreted letters but rejected that path because the cyst-implying letter C would still cause confusion.

What this means if you have PCOS now

If you already have a PCOS diagnosis, your situation does not change clinically. Your diagnosis, your medications, your management plan, and your symptoms are unchanged. The label on your chart will gradually shift from PCOS to PMOS over months to years as electronic health record systems, ICD coding, and clinical templates catch up.

Practically:

You do not need a new diagnosis.
You do not need to re-verify your condition.
You do not need to change medications based on the name change alone.
You can expect both terms to be used interchangeably for the next 1 to 3 years.
Your specialists will adopt the new term at different rates. Endocrinologists and reproductive specialists will likely shift first; primary care and gynecology will follow.

The most useful thing the rename may unlock is better integration of your care. If your providers have been treating insulin resistance and cycle irregularity as separate problems, the new name forces them into the same clinical frame. That is the point.

What this means for women who suspect PMOS but are undiagnosed

If you have irregular cycles, signs of androgen excess (acne, hirsutism, hair thinning), weight regulation difficulty, or a family history, the rename does not change the path to diagnosis. The criteria are the same. The criteria require at least two of the following three features:

Ovulatory dysfunction (irregular or absent ovulation)
Clinical or biochemical signs of androgen excess
Polycystic ovarian morphology on ultrasound or elevated anti-Mullerian hormone

What may change is how primary care responds. A more transparent name may reduce the historic pattern where women with these symptoms were told they had "irregular periods" and prescribed birth control without further workup. Insulin testing and metabolic screening are likely to become more routine. The new framing makes those defaults harder to skip.

The cycle syncing connection

If you arrived at this post via cycle syncing content, here is the relevance. PMOS (the condition formerly called PCOS) affects roughly 1 in 10 menstruating women. For these women, the standard four-phase cycle syncing model does not apply cleanly because cycles are often anovulatory or irregular.

Cycle syncing as a practice is built around the assumption that follicular, ovulatory, and luteal phases follow each other in a predictable rhythm. When ovulation does not happen consistently, that rhythm does not exist in the same way. A more useful frame for women with PMOS is tracking individual symptoms (energy, mood, sleep quality, insulin response) across whatever cycle length is occurring, rather than trying to force a 28-day template.

Cycle syncing on birth control covers the related case where exogenous hormones suppress the natural rhythm. The principle is the same: when the standard model does not fit, track what is actually happening and adjust from there.

What to expect over the next 12 months

The rename will roll out unevenly:

Months 0 to 3 (May to August 2026): medical literature, academic talks, and specialty society newsletters use PMOS. Patient-facing materials begin to update.
Months 3 to 9: major patient advocacy organizations (PCOS Challenge, Verity, AskPCOS) update their branding and educational content.
Months 6 to 18: electronic health records, ICD-10 and ICD-11 coding, and insurance billing systems update. This is the slowest layer.
Months 12 to 24: PMOS becomes the default term in mainstream patient-facing media. PCOS persists as a legacy term.

During the transition, expect both names to be used. Search engines will treat them as related but not identical terms for a while. If you are looking for current information, search for both.

Sources to read

Teede H. et al. "Renaming polycystic ovary syndrome: a global consensus." The Lancet, May 2026.
The 2023 international evidence-based PCOS guideline (Teede et al.) remains the clinical reference for diagnostic and management criteria. The rename does not supersede those guidelines.
Monash University's Centre for Health Research and Implementation hosts the international PMOS guideline portal and the AskPCOS patient app (likely to rebrand to AskPMOS).

Bottom line

PCOS is now PMOS. The criteria, the symptoms, the management, and the underlying biology are all the same. The name shifts the framing from "you have cysts on your ovaries" to "you have a multi-system endocrine and metabolic condition with ovarian involvement". For most women that reframe will be a small administrative change. For the women whose care was fragmented across specialties that did not communicate, it may turn out to be more than that.

For a deeper look at what cycle syncing means when your cycle does not follow the standard model, see is cycle syncing legit and does cycle syncing work.